Spironolactone in Men: Testosterone Suppression, Gynecomastia, and Sexual Side Effects

Yes — through two mechanisms: (1) androgen receptor blockade prevents testosterone and DHT from activating target tissues (functional androgen deficiency even with normal serum T); (2) inhibition of CYP17 in steroidogenesis reduces actual testosterone production. Gynecomastia (common), ED, and reduced libido are the most common clinical manifestations. Serum testosterone may appear normal while functional androgenic activity is severely impaired.

Eplerenone (Inspra) is the key alternative — a selective mineralocorticoid receptor antagonist without anti-androgenic activity. It has equivalent efficacy to spironolactone for heart failure and hypertension without gynecomastia, ED, or testosterone effects. It is more expensive and less evidence-rich than spironolactone for some indications. Discuss with your cardiologist or nephrologist whether eplerenone is appropriate for your specific indication.

Partially — functional gynecomastia (glandular breast tissue proliferation) often regresses partially after stopping, but established glandular tissue in longstanding cases may persist. The earlier spironolactone is stopped or switched to eplerenone after gynecomastia appears, the better the regression. Established gynecomastia that does not regress after drug discontinuation may require surgical correction (subcutaneous mastectomy) in symptomatic men.

No — spironolactone is frequently prescribed for serious cardiac or renal indications where abrupt discontinuation carries real risk, including for heart failure specifically, where it has a documented mortality benefit. Sexual and hormonal side effects should be reported to the prescribing doctor, who can evaluate whether a dose reduction, a switch to eplerenone, or an alternative medication class is appropriate given the specific condition being treated. Self-discontinuing a cardiac medication to address a sexual side effect risks a worse outcome than the side effect itself.

Side effects are clearly dose-dependent — the 25mg/day dose commonly used for heart failure (as studied in RALES) has a meaningfully lower gynecomastia rate than the higher 50-200mg/day doses typically used for hypertension or hyperaldosteronism. This is why, when a dose adjustment is medically appropriate for the underlying condition, moving to the lowest effective dose is often tried before switching medications entirely. Not every man needs the higher dose range, and this is a reasonable specific question to raise with a prescriber if side effects appear.

Yes — gynecomastia in particular can develop gradually over months of continuous use rather than appearing immediately, since it results from cumulative androgen receptor blockade and glandular tissue changes rather than an acute reaction. This is why new breast tenderness or visible tissue changes should be reported even if a man has already been taking spironolactone without issue for an extended period, rather than being dismissed simply because the medication was previously well-tolerated.

Its anti-androgenic effects on spermatogenesis appear to be reversible in most men after discontinuation, since the mechanism is functional receptor blockade and steroidogenesis suppression rather than direct testicular tissue damage, but data specifically on long-term fertility outcomes after extended spironolactone use is limited. Men actively trying to conceive who are on spironolactone should raise this specifically with their prescriber, since a temporary switch to eplerenone or another approach during the conception window may be a reasonable option depending on the underlying condition being treated.

Individual sensitivity to androgen receptor blockade varies considerably, and factors like dose, treatment duration, baseline testosterone level, and individual androgen receptor density in target tissues all plausibly contribute to why some men tolerate spironolactone with minimal or no noticeable sexual or hormonal side effects while others experience them prominently even at similar doses. This variability is well-documented but not fully explained by current research, which is part of why side effects can't be reliably predicted in advance for a given individual — monitoring after starting the medication remains the most practical approach.

The end result — glandular breast tissue growth — looks similar regardless of cause, but the mechanism differs from other common causes like obesity-related fat accumulation (pseudogynecomastia) or aging-related shifts in the testosterone-to-estrogen ratio. Spironolactone's version comes specifically from androgen receptor blockade plus mild progestogenic activity, which is why switching away from spironolactone (rather than addressing weight or general hormone balance) is the targeted fix when it's the identified cause, whereas other causes of gynecomastia require different underlying interventions.

Timing relative to starting the medication is the most useful clue — new breast tenderness or tissue growth that begins or clearly worsens after starting spironolactone strongly suggests a drug-related cause. A doctor may also examine whether the tissue change is glandular (firm, disc-like tissue beneath the nipple, consistent with true gynecomastia) versus generalized fat distribution (pseudogynecomastia from weight gain), since the two require different management approaches even though spironolactone can theoretically contribute to both through separate mechanisms.

Coverage varies by plan, but eplerenone is FDA-approved for several of the same indications as spironolactone (heart failure, hypertension), which generally supports coverage when a documented medical reason — like a genuine adverse reaction to spironolactone — is on record. Because eplerenone is typically more expensive than generic spironolactone, some insurers require documentation of the spironolactone side effect or a prior-authorization process before approving the switch, which is worth discussing with the prescribing doctor's office in advance.